Tim M. Mayleben
2014 - Esperion Therapeutics
In 2014, Tim M. Mayleben earned a total compensation of $750K as President and Chief Executive Officer at Esperion Therapeutics, a 78% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $300,000 |
|---|---|
| Salary | $450,000 |
| Total | $750,000 |
Mayleben received $450K in salary, accounting for 60% of the total pay in 2014.
Mayleben also received $300K in non-equity incentive plan.
Rankings
In 2014, Tim M. Mayleben's compensation ranked 8,783rd out of 13,032 executives tracked by ExecPay. In other words, Mayleben earned more than 32.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,783 out of 13,032 | 33rd |
Division Manufacturing | 3,270 out of 4,965 | 34th |
Major group Chemicals And Allied Products | 1,110 out of 1,690 | 34th |
Industry group Drugs | 884 out of 1,369 | 35th |
Industry Pharmaceutical Preparations | 673 out of 1,042 | 35th |
Source: SEC filing on March 6, 2017.
Mayleben's colleagues
We found two more compensation records of executives who worked with Tim M. Mayleben at Esperion Therapeutics in 2014.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019